Disease · MONDO_0015943
eosinophilic granulomatosis with polyangiitis
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. eosinophilic granulomatosis with polyangiitis. Diseases, record MONDO_0015943. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015943
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Allergic granulomatosis angiitis (disorder), CSS, Churg Strauss Syndrome, Churg-Strauss vasculitis, EGPA, Polyarteritis with lung involvement, allergic angiitides, allergic angiitides, granulomatous, allergic angiitis, allergic angiitis and granulomatosis, allergic angiitis, granulomatous, allergic granulomatoses, allergic granulomatosis, allergic granulomatous Angiitides, allergic granulomatous and angiitis, allergic granulomatous angiitis, angiitides, allergic, angiitides, allergic granulomatous, angiitides, granulomatous allergic, angiitis, allergic, angiitis, allergic granulomatous, angiitis, granulomatous allergic, eosinophilic granulomatous Vasculitides, eosinophilic granulomatous vasculitis, granulomatoses, allergic, granulomatosis, allergic, granulomatous allergic Angiitides, granulomatous allergic angiitis, granulomatous angiitides, allergic, granulomatous angiitis, allergic, granulomatous vasculitides, eosinophilic, granulomatous vasculitis, eosinophilic, syndrome, Churg-Strauss, vasculitides, eosinophilic granulomatous, vasculitis, Churg Strauss, vasculitis, eosinophilic granulomatous
- Open Targets
- Highest stage of its drugs
- Phase 3, for 14 of its 19 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs19
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| MEPOLIZUMAB | CHEMBL2108429 | Antibody | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| BENRALIZUMAB | CHEMBL1742991 | Antibody | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| AZATHIOPRINE | CHEMBL1542 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BETAMETHASONE | CHEMBL632 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| BETAMETHASONE SODIUM PHOSPHATE | CHEMBL1200762 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| HYDROCORTISONE | CHEMBL389621 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
1 to 10 of 19
See all 19 drugsTargets9
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 8 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| IL5 | Interleukin-5 | 3 | Interleukin-5 inhibitor | Phase 3 | https://conductscience.org/library/genes/3567 | Drugs and targets |
| C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 1 | C5a anaphylatoxin chemotactic receptor antagonist | Phase 2 | https://conductscience.org/library/genes/728 | Drugs and targets |
| DHFR | Dihydrofolate reductase | 1 | Dihydrofolate reductase inhibitor | Phase 2 | https://conductscience.org/library/genes/1719 | Drugs and targets |
| IL5RA | Interleukin-5 receptor subunit alpha | 1 | Interleukin-5 receptor subunit alpha inhibitor | Phase 3 | https://conductscience.org/library/genes/3568 | Drugs and targets |
| MS4A1 | B-lymphocyte antigen CD20 | 1 | B-lymphocyte antigen CD20 binding agent | Phase 3 | https://conductscience.org/library/genes/931 | Drugs and targets |
| PPAT | Amidophosphoribosyltransferase | 1 | Amidophosphoribosyltransferase inhibitor | Phase 3 | https://conductscience.org/library/genes/5471 | Drugs and targets |
| TNF | Tumor necrosis factor | 1 | TNF-alpha inhibitor | Unknown | https://conductscience.org/library/genes/7124 | Drugs and targets |
| TSLP | Thymic stromal lymphopoietin | 1 | Thymic stromal lymphopoietin inhibitor | Phase 2 | https://conductscience.org/library/genes/85480 | Drugs and targets |
Trials19
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03557060 | NUCALA® Special Drug Use Investigation (EGPA, Long-term) | 4,115 | 2026-02-18 | Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis | MEPOLIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04157348 | Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. | Phase 3 | 140 | 2025-01-14 | Eosinophilic Granulomatous Vasculitis | BENRALIZUMAB, MEPOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02020889 | A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis | Phase 3 | 136 | 2018-01-26 | Churg-Strauss Syndrome | MEPOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00527566 | Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome | Phase 1/2 | 10 | 2017-03-22 | Churg Strauss Syndrome | MEPOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00424749 | Rituxan in Churg Strauss Syndrome With Renal Involvement | Phase 2 | 4 | 2011-12-08 | Churg-Strauss Syndrome | RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT07591753 | Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study) | 299 | Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA) | MEPOLIZUMAB | Its record names the disease | ClinicalTrials.gov | ||
| NCT07444567 | Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment | Phase 3 | 230 | Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES) | BENRALIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00647166 | Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) | Phase 3 | 114 | MPA, PAN or EGPA With FFS=0, At Diagnosis or Within the First 15 Days Following Initiation of Corticosteroids | AZATHIOPRINE | Its record names the disease | ClinicalTrials.gov | |
| NCT02807103 | Rituximab in Eosinophilic Granulomatosis With Polyangiitis | Phase 3 | 107 | Eosinophilic Granulomatosis With Polyangiitis (EGPA) | CYCLOPHOSPHAMIDE, RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00001256 | Steroids and Methotrexate to Treat Systemic Vasculitis | Phase 2 | 100 | Inflammation, Vasculitis, Wegener's Granulomatosis | METHOTREXATE, PREDNISONE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 19
See all 19 trialsComparisons in its trials9
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Benralizumab 30 mg vs Mepolizumab 300 mg: Supportive Endpoint: Proportion of Subjects Who Achieved Supportive Remission at Both Weeks 36 and 48 | 55 of 70 | 52 of 70 | 140 | NCT04157348 | Trial comparisons |
| Benralizumab 30 mg vs Mepolizumab 300 mg: Number of Subjects Who Achieved Main Remission at Both Weeks 36 and 48 | 40 of 70 | 40 of 70 | 140 | NCT04157348 | Trial comparisons |
| Mepolizumab 300mg vs Placebo: Number of Participants Who Are in Remission at 36 and 48 Weeks | 28 of 68 | 7 of 68 | 136 | NCT02020889 | Trial comparisons |
| Mepolizumab 300mg vs Placebo: Number of Participants Who Are in Remission at 36 and 48 Weeks | 22 of 68 | 2 of 68 | 136 | NCT02020889 | Trial comparisons |
| Mepolizumab 300mg vs Placebo: Number of Participants Who Achieved Remission Within the First 24 Weeks and Remained in Remission for the Remainder of the Treatment Period | 13 of 68 | 1 of 68 | 136 | NCT02020889 | Trial comparisons |
| Mepolizumab 300mg vs Placebo: Time to First EGPA Relapse | 38 of 68 | 56 of 68 | 136 | NCT02020889 | Trial comparisons |
| Mepolizumab 300mg vs Placebo: deaths from any cause | 1 of 68 | 0 of 68 | 136 | NCT02020889 | Trial comparisons |
Mepolizumab 300mg vs Placebo: Number of Participants Who Achieved Remission (BVAS=0 and Prednisolone/Prednisone <=7.5 mg/Day) Within the First 24 Weeks and Remained in Remission for the Remainder of the Treatment Period | 16 of 68 | 2 of 68 | 136 | NCT02020889 | Trial comparisons |
| Mepolizumab 300mg vs Placebo: serious adverse events | 12 of 68 | 18 of 68 | 136 | NCT02020889 | Trial comparisons |
Papers from its trials21
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015943
GET https://conductscience.org/api/diseases/v1/MONDO_0015943/papers?page=2